SlideShare uma empresa Scribd logo
1 de 37
Baixar para ler offline
UNDERSTANDING
CLINICAL TRIALS
STATISTICS
DR.MAGDY KHAMES ALY
CRITICAL CARE MEDICINE
ZMH ALBATAYEH
OVERVIEW
 Clinicians examine and intervene with individual patients, must take
clinical decision on a sold base according to guidelines that evidence-
based.
 Statistical analysis is one of the foundations of evidence-based clinical
practice, a key in conducting new clinical research and in evaluating
and applying prior research.
 Reading and getting through clinical trials and researches is most
important part in our daily practice.
 Understanding basic statistical concepts will allow you to become a
more critical consumer of the medical literature, and ultimately be
able to produce better research and make better clinical decisions.
OBJECTIVES
 Describe how to interpret the results of a trial, including what
statistical significance means.
 Appreciate that results of trials have a direction, size, and
statistical significance
 Understand the information provided by P values and
confidence intervals
 Know how to interpret statistical significance
 Appreciate when there is an important difference between the
treatment and control arms of a trial.
CLINICAL TRIALS
Classification of Clinical trails:
Experimental(Intervention)
Randomized Controlled Trials (RCT)
Non-randomized Trials
 Epidemiologic
Observational
Cohort studies
Case-control studies
Cross-sectional studies
 Non-epidemiologic: Case-study (Case-series)
Opinion from a specialist based on biological and clinical principles
Importance
as
an evidence
CLINICAL TRIALS
Classification of Study Design
CROSS SECTIONAL
PROSPECTIVE COHORT
RETROSPECTIVE CASE-CONTROL
RETROSPECTIVE COHORT
PROSPECTIVE CASE-CONTROL
PAST CURRENT FUTURE
CLINICAL TRIALS
CONCEPTS AND TERMINOLOGY:
Cohort:
A group of people who share a common characteristics, sample subjects without
knowing their outcome status.
Case-Control Study:
Need to know who has an outcome when deciding which subjects to include in a
study.
Follow to observe their outcome
Compare their exposure status
CLINICAL TRIALS
COHORT STUDY CASE-CONTROL STUDY
Smoker Non-smoker With Lung Cancer Without Lung Cancer
N= 4000 N=4000 N=200 N=200
Lung CA - Lung CA + Lung CA - Lung CA + Non-smoker Smoker Non-smoker Smoker
N= 3800 N=200 N=3950 N=50 N=40 N=160 N=180 N=20
CLINICAL TRIALS
CLINICAL TRIALS
BIAS
 Bias is the intentional or unintentional adjustment in the
design and/or conduct of a Clinical trial, and analysis and
evaluation of the data that may affect the results.
Bias may affect the results of a clinical trial and cause them to be
unreliable.
Bias can occur at any phase of research, e.g. during trial design,
data collection, data analysis and publication.
CLINICAL TRIALS
MAJOR TYPES OF BIAS:
 Selection bias
Occurs when the selection of subjects into a sample or their allocation to a treatment group
produces a sample that is not representative of the population, or treatment groups that are
systematically different
prevented by random selection and random allocation
 Detection bias
Occurs when observations in one group are not sought as diligently as in the other
prevented by observer blinding
 Observer bias
Occurs when the observer is able to be subjective about the outcome
prevented by observer blinding and outcome measure design
CLINICAL TRIALS
MAJOR TYPES OF BIAS:
 Recall bias
Occurs when patients know which group they have been allocated to,
Which influences the way they report past history and symptoms
ie. if patient knows the are in the placebo group they may exaggerate their ‘untreated’ symptoms
Prevented by patient blinding
 Response bias
Occurs when patients who enroll in a trial may not represent those of the population as a whole
ie. the obese patients who enroll in a weight loss medication trial may be more motivated than those
in the general population
Prevention -> random sampling from population
CLINICAL TRIALS
MAJOR TYPES OF BIAS:
 Publication bias
Occurs because negative studies less likely to be submitted and/or published than positive ones
prevented by clinical trials registries and ensuring all well conducted studies are submitted and published (should be
mandatory)
in meta-analysis, the possibility of absent negative studies should be sought for by funnel plot analysis
 Regression to the mean
Occurs when random effects may cause a rare, extreme variation on a measurement if the measurement is repeated, the
likelihood is that the measurement will be less extreme thus, if a treatment had been given after the first measurement, it would
erroneously appear, on the basis of the second measurement, that it had had an effect
prevented by having a control group
 Hawthorne effect
Occurs when the process of studying and following up patients itself influences the outcome
ie. chronic headache may improve in patients who are being studied and regularly followed up
prevented by having a control group and masking the intention of study from patients and observers
Biostatistics
Tools used to
Analyze
Present
InterpretMake clinical decisions
Collect
Organize
Biostatistics
TYPES OF STATISTICS:
 To Organize Use information from
 Display descriptive statistics to
 Describe data using tables, make decisions or predictions
graphs about a population
Descriptive Inferential
Biostatistics
 STANDARD DEVIATION
 HOW TO USE SD
 PROBABILITY: (P value)
 CONFIDENCE INTERVAL
 ODDS AND ODDS RATIO
 RISK AND RISK RATIO
 CALCULATE NNT
 HOW TO INTERPRET A CLINICAL TRIAL
Biostatistics
STANDARD DEVIATION(SD):
Standard deviation (SD) is used for data which are “normally distributed” , to
provide information on how much the data vary around their mean.
SD indicates how much a set of values is spread around the average.
A range of one SD above and below the mean
 (abbreviated to ± 1 SD) includes 68.2% of the values.
 ± 2 SD includes 95.4% of the data.
 ± 3 SD includes 99.7%.
 Bell shaped curve when normally distributed
Biostatistics
STANDARD DEVIATION(SD):
Biostatistics
STANDARD DEVIATION(SD):
SD should only be used when the data have a normal distribution. However,
means and SDs are often wrongly used for data which are not normally
distributed.
A simple check for a normal distribution is to see if 2SDs away from the mean
are still within the possible range for the variable.
For example, if we have some length of hospital stay data with a mean stay of
10 days and a SD of 8 days then:
mean – (2 × SD) = 10 – (2 × 8) = 10 – 16 = –6 days.
This is clearly an impossible value for length of stay ( out of range), so the
data cannot be normally distributed. The mean and SDs are therefore not
appropriate measures to use.
Biostatistics
MEDIAN AND INTERQUIRTILE RANGE(IQR):
 Median used in case of SKEWED result (not normally distributed)
 IQR: it’s a range of result
Presenting 3 percentages:
25% of results
50% which is the Median
75% of the results
Biostatistics
Biostatistics
Biostatistics
PROBABILITY (P value):
The P (probability) value is used when we wish to see how likely a hypothesis
is true. The hypothesis is usually that there is no difference between two
treatments, known as the “null hypothesis”.
Null hypothesis:
The Original rule of any comparison or testing something is that no difference
or no effect, the role of biostatistics and P value is to disprove that. Null
hypothesis is impossible to prove it only can be disproved.
You can say that the Null hypothesis not true and there is difference between
two treatment.
The question the P value try to answer is this difference is significant and I
can depend on to make clinical decision or not.
Biostatistics
 The P value gives the probability of any observed difference have happened by
chance (the probability of play of chance)
 P = 0.5 means that the probability of a difference this large or larger have
happened by chance is 0.5 in 1, or 50:50.
 P = 0.05 means that the probability of a difference this large or larger have
happened by chance is 0.05 in 1, i.e. 1 in 20.
 The lower the P value, the less likely it is that the difference happened by chance
and so the higher the significance of the finding.
 P = 0.01 is often considered to be “highly significant”. It means that a difference
of this size or larger will only have happened by chance 1 in 100 times. This is
unlikely, but still possible.
 P = 0.001 means that a difference of this size or larger will have happened by
chance 1 in 1000 times, even less likely, but still just possible. It is usually
considered to be “very highly significant”.
Biostatistics
Pit falls of P-value:
 P-value becomes larger with a smaller difference.
 P-value becomes larger with a smaller sample size.
Thus, we cannot really tell why statistical significance is absent, due to small effect, or
small sample size?
 Not to confuse statistical significance with clinical relevance. If a study is too small,
the results are unlikely to be statistically significant even if the intervention actually
works.
 Conversely a large study may find a statistically significant difference that is too
small to have any clinical relevance.
Biostatistics
In this table we can say that the admission APACHII score and Antibiotic delay have
HIGH STATISTICALLY SIGNIFCANT impact on hospital mortality
Biostatistics
Confidence intervals CI:
Confidence intervals (CI) are typically used when, instead of simply
wanting the mean value of a sample, we want a range that is likely to
contain the true population value. This “true value” is the mean value that
we would get if we had data for the whole population.
Statisticians can calculate a range (interval) in which we can be fairly sure
(confident) that the “true value” lies.
Biostatistics
Relationship between p-value and 95% Confidence Interval, CI:
95% CI including the null value P>0.05 No difference detected
95% CI excluding the null value P<=0.05 A difference detected
Null value = 1 when a ratio between two means (or proportions) is evaluated.
Null value = 0 when a difference between two means is evaluated.
Biostatistics
Biostatistics
SD and CI:
Standard deviation tells us about the variability (spread) in a sample. The CI
tells us the range in which the true value (the mean if the sample were
infinitely large) is likely to be. Use SD to describe sampled data, and use 95%
CI to make statistical inference.
Meta-analysis CI 95% graph:
A technique for bringing together results from a number of similar
studies to give one overall estimate of effect.
Biostatistics
Risk and Risk ratio(RR):
Risk:
Is the probability that an event will happen.
It is calculated by dividing the number of events by the number of people at risk.
E.g: if 2 from 10 patients taking aspirin will bleed so the Risk of bleeding is 2/10=0.2
Risk Ratio(RR):
Risk in treatment group divided by Risk in controlled group (to compare the 2 Risks)
If RR > 1 that means the Risk increased in treatment group
If RR < 1 that means the Risk increased in control group
If RR = 1 means no difference.
Biostatistics
Odds and Odds ratio:
Odds:
Used by epidemiologists in studies looking for factors which do harm, it is a way of
comparing patients who already have a certain condition (cases) with patients who
do not (controls) – a “case–control study”.
calculated by dividing the number of times an event happens by the number of
times it does not happen.
E.g: 2 of 10 patients taking aspirin have bleeding Odds is 2/8=0.25
Odds ratio:
Calculated by dividing the odds of having been exposed to a risk factor by the odds in
the control group.
Biostatistics
Odds ratio:
An odds ratio of 1 indicates no difference in risk between the groups, i.e. the
odds in each group are the same.
If the odds ratio of an event is >1, the rate of that event is increased in patients
who have been exposed to the risk factor.
If <1, the rate of that event is reduced.
Biostatistics
Risk reduction and numbers needed to treat(NNT):
Risk reduction:
It refer to Relative or Absolute Risk Reduction(RRR,ARR) and it answer and
quantify how often the treatment or intervention works?
ARR is the difference between the event rate in the intervention group and that in
the control group. It is usually given as a percentage.
RRR is the proportion by which the intervention reduces the event rate. It is
calculated by dividing the ARR by the control event rate.
NNT is the number of patients who need to be treated for one to get benefit.
It is 100 divided by the ARR, i.e. NNT = 100/ARR
Biostatistics
Risk reduction and numbers needed to treat(NNT):
In a study testing the effect of a new antihypertensive patients 100 patient have been given the
new treatment and another 100 have been given placebo and followed up for 1 month the results
shown:
 ARR : (improved drug group – improved placebo group): 80%-60%=20% so ARR=20%
 NNT: (100/ARR) 100/20=5 so we need at least 5 patient taking the drug to see the effect in
1 of them.
 RRR: (ARR/event or not improved in Control group) 20/40=0.5 so RRR is 50% by this drug
Antihypertensive group Placebo group
Improved Not improved Improved Not improved
80 20 60 40
SUMMARY
 Mean and Standard deviation are useful when data are normally distributed,
otherwise, you may consider using Median and Inter-quartile range because they
are more robust for data distribution.
 P-value indicates the probability of falsely detecting a difference when there is no
difference. Larger effect and larger sample size leads to more significant result
(smaller p-value). So even clinically meaningless difference could reach statistical
significance, so be careful.
 Using confidence interval can refer statistical significance. When 95% CI does not
include null value, which links with P < 0.05.
 Use SD to describe sampled data, and use 95% CI to make statistical inference.
 Biostatistics are important topic to learn if you keen to be up-to-date with medical
researches and literatures
References
 Harris M, Taylor G, Dunitz M. Medical Statistics Made Easy. London and New York: 3rd
edition; 2014.
 Altman DG, Bland JM. Absence of evidence is not evidence of absence. BMJ
1995;311(7003):485.
 Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-
analyses. BMJ 2003;327(7414):557-60.
 Barratt A, Wyer PC, Hatala R, et al. Tips for learners of evidence-based medicine: 1.
Relative risk reduction, absolute risk reduction and number needed to treat. CMAJ
2004;171(4):353-8.
 Cates C. P values and confidence intervals (Update Article 2005). [Full text
(http://www.nntonline.net/pvalues-and-confidence-intervals/)]
 Guyatt G, Jaeschke R, Heddle N, Cook D, Shannon H, Walter S. Basic statistics for
clinicians: 1. Hypothesis testing. CMAJ 1995;152(1):27-32.
Understanding clinical trial's statistics

Mais conteúdo relacionado

Mais procurados

clinical trials types and design
clinical trials types and designclinical trials types and design
clinical trials types and designUttara Joshi
 
Interim analysis in clinical trials (1)
Interim analysis in clinical trials (1)Interim analysis in clinical trials (1)
Interim analysis in clinical trials (1)ADITYA CHAKRABORTY
 
Pharmacovigilance signal and signal detection
Pharmacovigilance signal and signal detectionPharmacovigilance signal and signal detection
Pharmacovigilance signal and signal detectionKiranRajput38
 
Biostatistics Roles and Responsibilities in Clinical Research | Pubrica
Biostatistics Roles and Responsibilities in Clinical Research | PubricaBiostatistics Roles and Responsibilities in Clinical Research | Pubrica
Biostatistics Roles and Responsibilities in Clinical Research | PubricaPubrica
 
Introduction to Clinical trial
Introduction to Clinical trial Introduction to Clinical trial
Introduction to Clinical trial rx_sonali
 
Introduction to clinical research
Introduction to clinical researchIntroduction to clinical research
Introduction to clinical researchPradeep H
 
Randomisation techniques
Randomisation techniquesRandomisation techniques
Randomisation techniquesUrmila Aswar
 
Biostatistics in Clinical Research
Biostatistics in Clinical ResearchBiostatistics in Clinical Research
Biostatistics in Clinical ResearchAbhaya Indrayan
 
Clinical trial design
Clinical trial designClinical trial design
Clinical trial designUrmila Aswar
 
Clinical trial design, Trial Size, and Study Population
Clinical trial design, Trial Size, and Study Population Clinical trial design, Trial Size, and Study Population
Clinical trial design, Trial Size, and Study Population Shubham Chinchulkar
 
randomized clinical trials I
randomized clinical trials Irandomized clinical trials I
randomized clinical trials IIAU Dent
 
protocol writing in clinical research
protocol writing in clinical research protocol writing in clinical research
protocol writing in clinical research pavithra vinayak
 
Clinical trials its types and designs
Clinical trials  its types and designsClinical trials  its types and designs
Clinical trials its types and designsDevesh Aggarwal
 
Basics of Systematic Review and Meta-analysis: Part 3
Basics of Systematic Review and Meta-analysis: Part 3Basics of Systematic Review and Meta-analysis: Part 3
Basics of Systematic Review and Meta-analysis: Part 3Rizwan S A
 

Mais procurados (20)

clinical trials types and design
clinical trials types and designclinical trials types and design
clinical trials types and design
 
Clinical trial design
Clinical trial designClinical trial design
Clinical trial design
 
CLINICAL TRIAL PROTOCOL
CLINICAL TRIAL PROTOCOLCLINICAL TRIAL PROTOCOL
CLINICAL TRIAL PROTOCOL
 
Interim analysis in clinical trials (1)
Interim analysis in clinical trials (1)Interim analysis in clinical trials (1)
Interim analysis in clinical trials (1)
 
Pharmacovigilance signal and signal detection
Pharmacovigilance signal and signal detectionPharmacovigilance signal and signal detection
Pharmacovigilance signal and signal detection
 
Biostatistics Roles and Responsibilities in Clinical Research | Pubrica
Biostatistics Roles and Responsibilities in Clinical Research | PubricaBiostatistics Roles and Responsibilities in Clinical Research | Pubrica
Biostatistics Roles and Responsibilities in Clinical Research | Pubrica
 
Medical research
Medical researchMedical research
Medical research
 
ICH-GCP Guidelines
ICH-GCP GuidelinesICH-GCP Guidelines
ICH-GCP Guidelines
 
Introduction to Clinical trial
Introduction to Clinical trial Introduction to Clinical trial
Introduction to Clinical trial
 
Introduction to clinical research
Introduction to clinical researchIntroduction to clinical research
Introduction to clinical research
 
Randomisation techniques
Randomisation techniquesRandomisation techniques
Randomisation techniques
 
Biostatistics in Clinical Research
Biostatistics in Clinical ResearchBiostatistics in Clinical Research
Biostatistics in Clinical Research
 
Clinical trial design
Clinical trial designClinical trial design
Clinical trial design
 
Clinical trial design, Trial Size, and Study Population
Clinical trial design, Trial Size, and Study Population Clinical trial design, Trial Size, and Study Population
Clinical trial design, Trial Size, and Study Population
 
randomized clinical trials I
randomized clinical trials Irandomized clinical trials I
randomized clinical trials I
 
protocol writing in clinical research
protocol writing in clinical research protocol writing in clinical research
protocol writing in clinical research
 
Clinical trials its types and designs
Clinical trials  its types and designsClinical trials  its types and designs
Clinical trials its types and designs
 
Basics of Systematic Review and Meta-analysis: Part 3
Basics of Systematic Review and Meta-analysis: Part 3Basics of Systematic Review and Meta-analysis: Part 3
Basics of Systematic Review and Meta-analysis: Part 3
 
ICH GCP
ICH GCPICH GCP
ICH GCP
 
Clinical trials
Clinical trialsClinical trials
Clinical trials
 

Semelhante a Understanding clinical trial's statistics

Critical Appriaisal Skills Basic 1 | May 4th 2011
Critical Appriaisal Skills Basic 1 | May 4th 2011Critical Appriaisal Skills Basic 1 | May 4th 2011
Critical Appriaisal Skills Basic 1 | May 4th 2011NES
 
Overview of different statistical tests used in epidemiological
Overview of different  statistical tests used in epidemiologicalOverview of different  statistical tests used in epidemiological
Overview of different statistical tests used in epidemiologicalshefali jain
 
Epidemological methods
Epidemological methodsEpidemological methods
Epidemological methodsKundan Singh
 
A Lenda do Valor P
A Lenda do Valor PA Lenda do Valor P
A Lenda do Valor PFUAD HAZIME
 
BIASES IN EPIDEMOLODY-1.pptx
BIASES IN EPIDEMOLODY-1.pptxBIASES IN EPIDEMOLODY-1.pptx
BIASES IN EPIDEMOLODY-1.pptxnaveen shyam
 
Statistics basics for oncologist kiran
Statistics basics for oncologist kiranStatistics basics for oncologist kiran
Statistics basics for oncologist kiranKiran Ramakrishna
 
Sample size estimation
Sample size estimationSample size estimation
Sample size estimationHanaaBayomy
 
Research methodology 101
Research methodology 101Research methodology 101
Research methodology 101Hesham Gaber
 
Sample Size Estimation and Statistical Test Selection
Sample Size Estimation  and Statistical Test SelectionSample Size Estimation  and Statistical Test Selection
Sample Size Estimation and Statistical Test SelectionVaggelis Vergoulas
 
Error, confounding and bias
Error, confounding and biasError, confounding and bias
Error, confounding and biasAmandeep Kaur
 
Lemeshow samplesize
Lemeshow samplesizeLemeshow samplesize
Lemeshow samplesize1joanenab
 
K7 - Critical Appraisal.pdf
K7 - Critical Appraisal.pdfK7 - Critical Appraisal.pdf
K7 - Critical Appraisal.pdfJeslynTengkawan1
 
Eblm pres final
Eblm pres finalEblm pres final
Eblm pres finalprasath172
 
Statistical significance vs Clinical significance
Statistical significance vs Clinical significanceStatistical significance vs Clinical significance
Statistical significance vs Clinical significanceVini Mehta
 

Semelhante a Understanding clinical trial's statistics (20)

Critical Appriaisal Skills Basic 1 | May 4th 2011
Critical Appriaisal Skills Basic 1 | May 4th 2011Critical Appriaisal Skills Basic 1 | May 4th 2011
Critical Appriaisal Skills Basic 1 | May 4th 2011
 
Overview of different statistical tests used in epidemiological
Overview of different  statistical tests used in epidemiologicalOverview of different  statistical tests used in epidemiological
Overview of different statistical tests used in epidemiological
 
Epidemological methods
Epidemological methodsEpidemological methods
Epidemological methods
 
A Lenda do Valor P
A Lenda do Valor PA Lenda do Valor P
A Lenda do Valor P
 
BIASES IN EPIDEMOLODY-1.pptx
BIASES IN EPIDEMOLODY-1.pptxBIASES IN EPIDEMOLODY-1.pptx
BIASES IN EPIDEMOLODY-1.pptx
 
Statistics basics for oncologist kiran
Statistics basics for oncologist kiranStatistics basics for oncologist kiran
Statistics basics for oncologist kiran
 
Sample size estimation
Sample size estimationSample size estimation
Sample size estimation
 
Research methodology 101
Research methodology 101Research methodology 101
Research methodology 101
 
Module7_RamdomError.pptx
Module7_RamdomError.pptxModule7_RamdomError.pptx
Module7_RamdomError.pptx
 
Sample Size Estimation and Statistical Test Selection
Sample Size Estimation  and Statistical Test SelectionSample Size Estimation  and Statistical Test Selection
Sample Size Estimation and Statistical Test Selection
 
Bias in clinical research
Bias in clinical research Bias in clinical research
Bias in clinical research
 
Error, confounding and bias
Error, confounding and biasError, confounding and bias
Error, confounding and bias
 
Lemeshow samplesize
Lemeshow samplesizeLemeshow samplesize
Lemeshow samplesize
 
Clinical epidemiology
Clinical epidemiologyClinical epidemiology
Clinical epidemiology
 
OBSERVATIONAL STUDIES PPT.pptx
OBSERVATIONAL STUDIES PPT.pptxOBSERVATIONAL STUDIES PPT.pptx
OBSERVATIONAL STUDIES PPT.pptx
 
Lund 2009
Lund 2009Lund 2009
Lund 2009
 
K7 - Critical Appraisal.pdf
K7 - Critical Appraisal.pdfK7 - Critical Appraisal.pdf
K7 - Critical Appraisal.pdf
 
Copenhagen 2008
Copenhagen 2008Copenhagen 2008
Copenhagen 2008
 
Eblm pres final
Eblm pres finalEblm pres final
Eblm pres final
 
Statistical significance vs Clinical significance
Statistical significance vs Clinical significanceStatistical significance vs Clinical significance
Statistical significance vs Clinical significance
 

Mais de Magdy Khames Aly

Mais de Magdy Khames Aly (9)

Covid19 syndrome Best practice
Covid19 syndrome Best practiceCovid19 syndrome Best practice
Covid19 syndrome Best practice
 
Ecg in athletes and young age
Ecg in athletes and young ageEcg in athletes and young age
Ecg in athletes and young age
 
Antibiotics the icu weapon
Antibiotics the icu weaponAntibiotics the icu weapon
Antibiotics the icu weapon
 
Resuscitation and pefusion
Resuscitation and pefusionResuscitation and pefusion
Resuscitation and pefusion
 
Sepsis the serial killer
Sepsis the serial killerSepsis the serial killer
Sepsis the serial killer
 
SEPSIS BIOMARKERS UPDATES
SEPSIS BIOMARKERS UPDATESSEPSIS BIOMARKERS UPDATES
SEPSIS BIOMARKERS UPDATES
 
Toxidromes
ToxidromesToxidromes
Toxidromes
 
EMERGENCY RED FLAGS
EMERGENCY RED FLAGSEMERGENCY RED FLAGS
EMERGENCY RED FLAGS
 
Mechanical ventilation in emergency
Mechanical ventilation in emergencyMechanical ventilation in emergency
Mechanical ventilation in emergency
 

Último

Using Data Visualization in Public Health Communications
Using Data Visualization in Public Health CommunicationsUsing Data Visualization in Public Health Communications
Using Data Visualization in Public Health Communicationskatiequigley33
 
SGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdf
SGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdfSGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdf
SGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdfHongBiThi1
 
PAIN/CLASSIFICATION AND MANAGEMENT OF PAIN.pdf
PAIN/CLASSIFICATION AND MANAGEMENT OF PAIN.pdfPAIN/CLASSIFICATION AND MANAGEMENT OF PAIN.pdf
PAIN/CLASSIFICATION AND MANAGEMENT OF PAIN.pdfDolisha Warbi
 
Different drug regularity bodies in different countries.
Different drug regularity bodies in different countries.Different drug regularity bodies in different countries.
Different drug regularity bodies in different countries.kishan singh tomar
 
ORAL HYPOGLYCAEMIC AGENTS - PART 2.pptx
ORAL HYPOGLYCAEMIC AGENTS  - PART 2.pptxORAL HYPOGLYCAEMIC AGENTS  - PART 2.pptx
ORAL HYPOGLYCAEMIC AGENTS - PART 2.pptxNIKITA BHUTE
 
EXERCISE PERFORMANCE.pptx, Lung function
EXERCISE PERFORMANCE.pptx, Lung functionEXERCISE PERFORMANCE.pptx, Lung function
EXERCISE PERFORMANCE.pptx, Lung functionkrishnareddy157915
 
power point presentation of Clinical evaluation of strabismus
power point presentation of Clinical evaluation  of strabismuspower point presentation of Clinical evaluation  of strabismus
power point presentation of Clinical evaluation of strabismusChandrasekar Reddy
 
Female Reproductive Physiology Before Pregnancy
Female Reproductive Physiology Before PregnancyFemale Reproductive Physiology Before Pregnancy
Female Reproductive Physiology Before PregnancyMedicoseAcademics
 
Physiology of Smooth Muscles -Mechanics of contraction and relaxation
Physiology of Smooth Muscles -Mechanics of contraction and relaxationPhysiology of Smooth Muscles -Mechanics of contraction and relaxation
Physiology of Smooth Muscles -Mechanics of contraction and relaxationMedicoseAcademics
 
AORTIC DISSECTION and management of aortic dissection
AORTIC DISSECTION and management of aortic dissectionAORTIC DISSECTION and management of aortic dissection
AORTIC DISSECTION and management of aortic dissectiondrhanifmohdali
 
Generative AI in Health Care a scoping review and a persoanl experience.
Generative AI in Health Care a scoping review and a persoanl experience.Generative AI in Health Care a scoping review and a persoanl experience.
Generative AI in Health Care a scoping review and a persoanl experience.Vaikunthan Rajaratnam
 
AUTONOMIC NERVOUS SYSTEM organization and functions
AUTONOMIC NERVOUS SYSTEM organization and functionsAUTONOMIC NERVOUS SYSTEM organization and functions
AUTONOMIC NERVOUS SYSTEM organization and functionsMedicoseAcademics
 
Basic structure of hair and hair growth cycle.pptx
Basic structure of hair and hair growth cycle.pptxBasic structure of hair and hair growth cycle.pptx
Basic structure of hair and hair growth cycle.pptxkomalt2001
 
Role of Soap based and synthetic or syndets bar
Role of  Soap based and synthetic or syndets barRole of  Soap based and synthetic or syndets bar
Role of Soap based and synthetic or syndets barmohitRahangdale
 
CONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdf
CONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdfCONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdf
CONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdfDolisha Warbi
 
Bulimia nervosa ( Eating Disorders) Mental Health Nursing.
Bulimia nervosa ( Eating Disorders) Mental Health Nursing.Bulimia nervosa ( Eating Disorders) Mental Health Nursing.
Bulimia nervosa ( Eating Disorders) Mental Health Nursing.aarjukhadka22
 
SGK ĐIỆN GIẬT ĐHYHN RẤT LÀ HAY TUYỆT VỜI.pdf
SGK ĐIỆN GIẬT ĐHYHN        RẤT LÀ HAY TUYỆT VỜI.pdfSGK ĐIỆN GIẬT ĐHYHN        RẤT LÀ HAY TUYỆT VỜI.pdf
SGK ĐIỆN GIẬT ĐHYHN RẤT LÀ HAY TUYỆT VỜI.pdfHongBiThi1
 
pA2 value, Schild plot and pD2 values- applications in pharmacology
pA2 value, Schild plot and pD2 values- applications in pharmacologypA2 value, Schild plot and pD2 values- applications in pharmacology
pA2 value, Schild plot and pD2 values- applications in pharmacologyDeepakDaniel9
 

Último (20)

Using Data Visualization in Public Health Communications
Using Data Visualization in Public Health CommunicationsUsing Data Visualization in Public Health Communications
Using Data Visualization in Public Health Communications
 
How to master Steroid (glucocorticoids) prescription, different scenarios, ca...
How to master Steroid (glucocorticoids) prescription, different scenarios, ca...How to master Steroid (glucocorticoids) prescription, different scenarios, ca...
How to master Steroid (glucocorticoids) prescription, different scenarios, ca...
 
SGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdf
SGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdfSGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdf
SGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdf
 
PAIN/CLASSIFICATION AND MANAGEMENT OF PAIN.pdf
PAIN/CLASSIFICATION AND MANAGEMENT OF PAIN.pdfPAIN/CLASSIFICATION AND MANAGEMENT OF PAIN.pdf
PAIN/CLASSIFICATION AND MANAGEMENT OF PAIN.pdf
 
Different drug regularity bodies in different countries.
Different drug regularity bodies in different countries.Different drug regularity bodies in different countries.
Different drug regularity bodies in different countries.
 
ORAL HYPOGLYCAEMIC AGENTS - PART 2.pptx
ORAL HYPOGLYCAEMIC AGENTS  - PART 2.pptxORAL HYPOGLYCAEMIC AGENTS  - PART 2.pptx
ORAL HYPOGLYCAEMIC AGENTS - PART 2.pptx
 
EXERCISE PERFORMANCE.pptx, Lung function
EXERCISE PERFORMANCE.pptx, Lung functionEXERCISE PERFORMANCE.pptx, Lung function
EXERCISE PERFORMANCE.pptx, Lung function
 
GOUT UPDATE AHMED YEHIA 2024, case based approach with application of the lat...
GOUT UPDATE AHMED YEHIA 2024, case based approach with application of the lat...GOUT UPDATE AHMED YEHIA 2024, case based approach with application of the lat...
GOUT UPDATE AHMED YEHIA 2024, case based approach with application of the lat...
 
power point presentation of Clinical evaluation of strabismus
power point presentation of Clinical evaluation  of strabismuspower point presentation of Clinical evaluation  of strabismus
power point presentation of Clinical evaluation of strabismus
 
Female Reproductive Physiology Before Pregnancy
Female Reproductive Physiology Before PregnancyFemale Reproductive Physiology Before Pregnancy
Female Reproductive Physiology Before Pregnancy
 
Physiology of Smooth Muscles -Mechanics of contraction and relaxation
Physiology of Smooth Muscles -Mechanics of contraction and relaxationPhysiology of Smooth Muscles -Mechanics of contraction and relaxation
Physiology of Smooth Muscles -Mechanics of contraction and relaxation
 
AORTIC DISSECTION and management of aortic dissection
AORTIC DISSECTION and management of aortic dissectionAORTIC DISSECTION and management of aortic dissection
AORTIC DISSECTION and management of aortic dissection
 
Generative AI in Health Care a scoping review and a persoanl experience.
Generative AI in Health Care a scoping review and a persoanl experience.Generative AI in Health Care a scoping review and a persoanl experience.
Generative AI in Health Care a scoping review and a persoanl experience.
 
AUTONOMIC NERVOUS SYSTEM organization and functions
AUTONOMIC NERVOUS SYSTEM organization and functionsAUTONOMIC NERVOUS SYSTEM organization and functions
AUTONOMIC NERVOUS SYSTEM organization and functions
 
Basic structure of hair and hair growth cycle.pptx
Basic structure of hair and hair growth cycle.pptxBasic structure of hair and hair growth cycle.pptx
Basic structure of hair and hair growth cycle.pptx
 
Role of Soap based and synthetic or syndets bar
Role of  Soap based and synthetic or syndets barRole of  Soap based and synthetic or syndets bar
Role of Soap based and synthetic or syndets bar
 
CONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdf
CONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdfCONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdf
CONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdf
 
Bulimia nervosa ( Eating Disorders) Mental Health Nursing.
Bulimia nervosa ( Eating Disorders) Mental Health Nursing.Bulimia nervosa ( Eating Disorders) Mental Health Nursing.
Bulimia nervosa ( Eating Disorders) Mental Health Nursing.
 
SGK ĐIỆN GIẬT ĐHYHN RẤT LÀ HAY TUYỆT VỜI.pdf
SGK ĐIỆN GIẬT ĐHYHN        RẤT LÀ HAY TUYỆT VỜI.pdfSGK ĐIỆN GIẬT ĐHYHN        RẤT LÀ HAY TUYỆT VỜI.pdf
SGK ĐIỆN GIẬT ĐHYHN RẤT LÀ HAY TUYỆT VỜI.pdf
 
pA2 value, Schild plot and pD2 values- applications in pharmacology
pA2 value, Schild plot and pD2 values- applications in pharmacologypA2 value, Schild plot and pD2 values- applications in pharmacology
pA2 value, Schild plot and pD2 values- applications in pharmacology
 

Understanding clinical trial's statistics

  • 1. UNDERSTANDING CLINICAL TRIALS STATISTICS DR.MAGDY KHAMES ALY CRITICAL CARE MEDICINE ZMH ALBATAYEH
  • 2. OVERVIEW  Clinicians examine and intervene with individual patients, must take clinical decision on a sold base according to guidelines that evidence- based.  Statistical analysis is one of the foundations of evidence-based clinical practice, a key in conducting new clinical research and in evaluating and applying prior research.  Reading and getting through clinical trials and researches is most important part in our daily practice.  Understanding basic statistical concepts will allow you to become a more critical consumer of the medical literature, and ultimately be able to produce better research and make better clinical decisions.
  • 3. OBJECTIVES  Describe how to interpret the results of a trial, including what statistical significance means.  Appreciate that results of trials have a direction, size, and statistical significance  Understand the information provided by P values and confidence intervals  Know how to interpret statistical significance  Appreciate when there is an important difference between the treatment and control arms of a trial.
  • 4. CLINICAL TRIALS Classification of Clinical trails: Experimental(Intervention) Randomized Controlled Trials (RCT) Non-randomized Trials  Epidemiologic Observational Cohort studies Case-control studies Cross-sectional studies  Non-epidemiologic: Case-study (Case-series) Opinion from a specialist based on biological and clinical principles Importance as an evidence
  • 5. CLINICAL TRIALS Classification of Study Design CROSS SECTIONAL PROSPECTIVE COHORT RETROSPECTIVE CASE-CONTROL RETROSPECTIVE COHORT PROSPECTIVE CASE-CONTROL PAST CURRENT FUTURE
  • 6. CLINICAL TRIALS CONCEPTS AND TERMINOLOGY: Cohort: A group of people who share a common characteristics, sample subjects without knowing their outcome status. Case-Control Study: Need to know who has an outcome when deciding which subjects to include in a study. Follow to observe their outcome Compare their exposure status
  • 7. CLINICAL TRIALS COHORT STUDY CASE-CONTROL STUDY Smoker Non-smoker With Lung Cancer Without Lung Cancer N= 4000 N=4000 N=200 N=200 Lung CA - Lung CA + Lung CA - Lung CA + Non-smoker Smoker Non-smoker Smoker N= 3800 N=200 N=3950 N=50 N=40 N=160 N=180 N=20
  • 9. CLINICAL TRIALS BIAS  Bias is the intentional or unintentional adjustment in the design and/or conduct of a Clinical trial, and analysis and evaluation of the data that may affect the results. Bias may affect the results of a clinical trial and cause them to be unreliable. Bias can occur at any phase of research, e.g. during trial design, data collection, data analysis and publication.
  • 10. CLINICAL TRIALS MAJOR TYPES OF BIAS:  Selection bias Occurs when the selection of subjects into a sample or their allocation to a treatment group produces a sample that is not representative of the population, or treatment groups that are systematically different prevented by random selection and random allocation  Detection bias Occurs when observations in one group are not sought as diligently as in the other prevented by observer blinding  Observer bias Occurs when the observer is able to be subjective about the outcome prevented by observer blinding and outcome measure design
  • 11. CLINICAL TRIALS MAJOR TYPES OF BIAS:  Recall bias Occurs when patients know which group they have been allocated to, Which influences the way they report past history and symptoms ie. if patient knows the are in the placebo group they may exaggerate their ‘untreated’ symptoms Prevented by patient blinding  Response bias Occurs when patients who enroll in a trial may not represent those of the population as a whole ie. the obese patients who enroll in a weight loss medication trial may be more motivated than those in the general population Prevention -> random sampling from population
  • 12. CLINICAL TRIALS MAJOR TYPES OF BIAS:  Publication bias Occurs because negative studies less likely to be submitted and/or published than positive ones prevented by clinical trials registries and ensuring all well conducted studies are submitted and published (should be mandatory) in meta-analysis, the possibility of absent negative studies should be sought for by funnel plot analysis  Regression to the mean Occurs when random effects may cause a rare, extreme variation on a measurement if the measurement is repeated, the likelihood is that the measurement will be less extreme thus, if a treatment had been given after the first measurement, it would erroneously appear, on the basis of the second measurement, that it had had an effect prevented by having a control group  Hawthorne effect Occurs when the process of studying and following up patients itself influences the outcome ie. chronic headache may improve in patients who are being studied and regularly followed up prevented by having a control group and masking the intention of study from patients and observers
  • 13. Biostatistics Tools used to Analyze Present InterpretMake clinical decisions Collect Organize
  • 14. Biostatistics TYPES OF STATISTICS:  To Organize Use information from  Display descriptive statistics to  Describe data using tables, make decisions or predictions graphs about a population Descriptive Inferential
  • 15. Biostatistics  STANDARD DEVIATION  HOW TO USE SD  PROBABILITY: (P value)  CONFIDENCE INTERVAL  ODDS AND ODDS RATIO  RISK AND RISK RATIO  CALCULATE NNT  HOW TO INTERPRET A CLINICAL TRIAL
  • 16. Biostatistics STANDARD DEVIATION(SD): Standard deviation (SD) is used for data which are “normally distributed” , to provide information on how much the data vary around their mean. SD indicates how much a set of values is spread around the average. A range of one SD above and below the mean  (abbreviated to ± 1 SD) includes 68.2% of the values.  ± 2 SD includes 95.4% of the data.  ± 3 SD includes 99.7%.  Bell shaped curve when normally distributed
  • 18. Biostatistics STANDARD DEVIATION(SD): SD should only be used when the data have a normal distribution. However, means and SDs are often wrongly used for data which are not normally distributed. A simple check for a normal distribution is to see if 2SDs away from the mean are still within the possible range for the variable. For example, if we have some length of hospital stay data with a mean stay of 10 days and a SD of 8 days then: mean – (2 × SD) = 10 – (2 × 8) = 10 – 16 = –6 days. This is clearly an impossible value for length of stay ( out of range), so the data cannot be normally distributed. The mean and SDs are therefore not appropriate measures to use.
  • 19. Biostatistics MEDIAN AND INTERQUIRTILE RANGE(IQR):  Median used in case of SKEWED result (not normally distributed)  IQR: it’s a range of result Presenting 3 percentages: 25% of results 50% which is the Median 75% of the results
  • 22. Biostatistics PROBABILITY (P value): The P (probability) value is used when we wish to see how likely a hypothesis is true. The hypothesis is usually that there is no difference between two treatments, known as the “null hypothesis”. Null hypothesis: The Original rule of any comparison or testing something is that no difference or no effect, the role of biostatistics and P value is to disprove that. Null hypothesis is impossible to prove it only can be disproved. You can say that the Null hypothesis not true and there is difference between two treatment. The question the P value try to answer is this difference is significant and I can depend on to make clinical decision or not.
  • 23. Biostatistics  The P value gives the probability of any observed difference have happened by chance (the probability of play of chance)  P = 0.5 means that the probability of a difference this large or larger have happened by chance is 0.5 in 1, or 50:50.  P = 0.05 means that the probability of a difference this large or larger have happened by chance is 0.05 in 1, i.e. 1 in 20.  The lower the P value, the less likely it is that the difference happened by chance and so the higher the significance of the finding.  P = 0.01 is often considered to be “highly significant”. It means that a difference of this size or larger will only have happened by chance 1 in 100 times. This is unlikely, but still possible.  P = 0.001 means that a difference of this size or larger will have happened by chance 1 in 1000 times, even less likely, but still just possible. It is usually considered to be “very highly significant”.
  • 24. Biostatistics Pit falls of P-value:  P-value becomes larger with a smaller difference.  P-value becomes larger with a smaller sample size. Thus, we cannot really tell why statistical significance is absent, due to small effect, or small sample size?  Not to confuse statistical significance with clinical relevance. If a study is too small, the results are unlikely to be statistically significant even if the intervention actually works.  Conversely a large study may find a statistically significant difference that is too small to have any clinical relevance.
  • 25. Biostatistics In this table we can say that the admission APACHII score and Antibiotic delay have HIGH STATISTICALLY SIGNIFCANT impact on hospital mortality
  • 26. Biostatistics Confidence intervals CI: Confidence intervals (CI) are typically used when, instead of simply wanting the mean value of a sample, we want a range that is likely to contain the true population value. This “true value” is the mean value that we would get if we had data for the whole population. Statisticians can calculate a range (interval) in which we can be fairly sure (confident) that the “true value” lies.
  • 27. Biostatistics Relationship between p-value and 95% Confidence Interval, CI: 95% CI including the null value P>0.05 No difference detected 95% CI excluding the null value P<=0.05 A difference detected Null value = 1 when a ratio between two means (or proportions) is evaluated. Null value = 0 when a difference between two means is evaluated.
  • 29. Biostatistics SD and CI: Standard deviation tells us about the variability (spread) in a sample. The CI tells us the range in which the true value (the mean if the sample were infinitely large) is likely to be. Use SD to describe sampled data, and use 95% CI to make statistical inference. Meta-analysis CI 95% graph: A technique for bringing together results from a number of similar studies to give one overall estimate of effect.
  • 30. Biostatistics Risk and Risk ratio(RR): Risk: Is the probability that an event will happen. It is calculated by dividing the number of events by the number of people at risk. E.g: if 2 from 10 patients taking aspirin will bleed so the Risk of bleeding is 2/10=0.2 Risk Ratio(RR): Risk in treatment group divided by Risk in controlled group (to compare the 2 Risks) If RR > 1 that means the Risk increased in treatment group If RR < 1 that means the Risk increased in control group If RR = 1 means no difference.
  • 31. Biostatistics Odds and Odds ratio: Odds: Used by epidemiologists in studies looking for factors which do harm, it is a way of comparing patients who already have a certain condition (cases) with patients who do not (controls) – a “case–control study”. calculated by dividing the number of times an event happens by the number of times it does not happen. E.g: 2 of 10 patients taking aspirin have bleeding Odds is 2/8=0.25 Odds ratio: Calculated by dividing the odds of having been exposed to a risk factor by the odds in the control group.
  • 32. Biostatistics Odds ratio: An odds ratio of 1 indicates no difference in risk between the groups, i.e. the odds in each group are the same. If the odds ratio of an event is >1, the rate of that event is increased in patients who have been exposed to the risk factor. If <1, the rate of that event is reduced.
  • 33. Biostatistics Risk reduction and numbers needed to treat(NNT): Risk reduction: It refer to Relative or Absolute Risk Reduction(RRR,ARR) and it answer and quantify how often the treatment or intervention works? ARR is the difference between the event rate in the intervention group and that in the control group. It is usually given as a percentage. RRR is the proportion by which the intervention reduces the event rate. It is calculated by dividing the ARR by the control event rate. NNT is the number of patients who need to be treated for one to get benefit. It is 100 divided by the ARR, i.e. NNT = 100/ARR
  • 34. Biostatistics Risk reduction and numbers needed to treat(NNT): In a study testing the effect of a new antihypertensive patients 100 patient have been given the new treatment and another 100 have been given placebo and followed up for 1 month the results shown:  ARR : (improved drug group – improved placebo group): 80%-60%=20% so ARR=20%  NNT: (100/ARR) 100/20=5 so we need at least 5 patient taking the drug to see the effect in 1 of them.  RRR: (ARR/event or not improved in Control group) 20/40=0.5 so RRR is 50% by this drug Antihypertensive group Placebo group Improved Not improved Improved Not improved 80 20 60 40
  • 35. SUMMARY  Mean and Standard deviation are useful when data are normally distributed, otherwise, you may consider using Median and Inter-quartile range because they are more robust for data distribution.  P-value indicates the probability of falsely detecting a difference when there is no difference. Larger effect and larger sample size leads to more significant result (smaller p-value). So even clinically meaningless difference could reach statistical significance, so be careful.  Using confidence interval can refer statistical significance. When 95% CI does not include null value, which links with P < 0.05.  Use SD to describe sampled data, and use 95% CI to make statistical inference.  Biostatistics are important topic to learn if you keen to be up-to-date with medical researches and literatures
  • 36. References  Harris M, Taylor G, Dunitz M. Medical Statistics Made Easy. London and New York: 3rd edition; 2014.  Altman DG, Bland JM. Absence of evidence is not evidence of absence. BMJ 1995;311(7003):485.  Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta- analyses. BMJ 2003;327(7414):557-60.  Barratt A, Wyer PC, Hatala R, et al. Tips for learners of evidence-based medicine: 1. Relative risk reduction, absolute risk reduction and number needed to treat. CMAJ 2004;171(4):353-8.  Cates C. P values and confidence intervals (Update Article 2005). [Full text (http://www.nntonline.net/pvalues-and-confidence-intervals/)]  Guyatt G, Jaeschke R, Heddle N, Cook D, Shannon H, Walter S. Basic statistics for clinicians: 1. Hypothesis testing. CMAJ 1995;152(1):27-32.